Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 4
2012 2
2013 3
2014 3
2015 4
2016 8
2017 6
2018 6
2019 3
2020 2
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

43 results
Results by year
Filters applied: . Clear all
Page 1
Monoclonal antibodies therapies for ovarian cancer.
Leone Roberti Maggiore U, Bellati F, Ruscito I, Gasparri ML, Alessandri F, Venturini PL, Ferrero S. Leone Roberti Maggiore U, et al. Among authors: ruscito i. Expert Opin Biol Ther. 2013 May;13(5):739-64. doi: 10.1517/14712598.2013.767328. Epub 2013 Feb 4. Expert Opin Biol Ther. 2013. PMID: 23373587 Review.
BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.
Kalachand RD, Stordal B, Madden S, Chandler B, Cunningham J, Goode EL, Ruscito I, Braicu EI, Sehouli J, Ignatov A, Yu H, Katsaros D, Mills GB, Lu KH, Carey MS, Timms KM, Kupryjanczyk J, Rzepecka IK, Podgorska A, McAlpine JN, Swisher EM, Bernards SS, O'Riain C, O'Toole S, O'Leary JJ, Bowtell DD, Thomas DM, Prieske K, Joosse SA, Woelber L, Chaudhry P, Häfner N, Runnebaum IB, Hennessy BT. Kalachand RD, et al. Among authors: ruscito i. J Natl Cancer Inst. 2020 Dec 14;112(12):1190-1203. doi: 10.1093/jnci/djaa070. J Natl Cancer Inst. 2020. PMID: 32413141
Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer.
Gasparri ML, Casorelli A, Bardhi E, Besharat AR, Savone D, Ruscito I, Farooqi AA, Papadia A, Mueller MD, Ferretti E, Benedetti Panici P. Gasparri ML, et al. Among authors: ruscito i. Tumour Biol. 2017 May;39(5):1010428317695525. doi: 10.1177/1010428317695525. Tumour Biol. 2017. PMID: 28459207 Free article. Review.
PARP inhibition: A promising therapeutic target in ovarian cancer.
Musella A, Marchetti C, Gasparri ML, Salerno L, Casorelli A, Domenici L, Imperiale L, Ruscito I, Abdul Halim T, Palaia I, Di Donato V, Pecorini F, Monti M, Muzii L, Panici PB. Musella A, et al. Among authors: ruscito i. Cell Mol Biol (Noisy-le-grand). 2015 Oct 30;61(6):44-61. Cell Mol Biol (Noisy-le-grand). 2015. PMID: 26518896 Review.
Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.
Guan J, Darb-Esfahani S, Richter R, Taube ET, Ruscito I, Mahner S, Woelber L, Prieske K, Concin N, Vergote I, Van Nieuwenhuysen E, Achimas-Cadariu P, Glajzer J, Woopen H, Stanske M, Kulbe H, Denkert C, Sehouli J, Braicu EI. Guan J, et al. Among authors: ruscito i. J Cancer Res Clin Oncol. 2019 Apr;145(4):1063-1073. doi: 10.1007/s00432-019-02877-4. Epub 2019 Feb 27. J Cancer Res Clin Oncol. 2019. PMID: 30810838
Cediranib in ovarian cancer: state of the art and future perspectives.
Ruscito I, Gasparri ML, Marchetti C, De Medici C, Bracchi C, Palaia I, Imboden S, Mueller MD, Papadia A, Muzii L, Panici PB. Ruscito I, et al. Tumour Biol. 2016 Mar;37(3):2833-9. doi: 10.1007/s13277-015-4781-4. Epub 2016 Jan 11. Tumour Biol. 2016. PMID: 26753963 Review.
43 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page